secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0001193125-22-070007
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude appoints Jane Huang as President & CMO; updates pipeline prioritizing PRT811 and IV PRT1419
--------------------------------------------------------------------------------

- Appoints Jane Huang President & CMO effective April 4, 2022; compensation: $525k base, 50% bonus target, 150k RSUs, 460k options.
- Prioritizes PRT811 over PRT543 for PRMT5 program due to superior safety & brain penetration; expansion cohort data in 2H2022.
- New pipeline candidate PRT3645, a highly brain-penetrant CDK4/6 inhibitor; IND submission planned mid-2022.
- IV formulation of MCL1 inhibitor PRT1419 prioritized; combination trial with venetoclax starts mid-2022; RP2D by 2H2022.
- SMARCA2/BRM degrader progress; IND submission planned by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/0001193125-22-070007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/d641589d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-070007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer